TABLE 3.
Demographics and clinical data of patients with SII‐CG
| Age | Gender | Site | Histology | NAC | Time a to start | Time b to identify | Time a to finish | Camera System | TD fluorescence | TD recognition | ICG dose Mg (mg/kg) | SII‐ICG‐related complications | TD patterns | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 65 | M | Ut | SCC | DCF | 46 | 56 | 352 | Olympus | Yes | Yes | 20 (0.27) | No | Typical |
| 2 | 79 | F | Mt | SCC | FP | 46 | 91 | 296 | Olympus | Yes | Yes | 20 (0.48) | No | Duplication |
| 3 | 79 | M | Ae | Adeno | No | 30 | 86 | 221 | Stryker | Yes | Yes | 22 (0.37) | No | Branching |
| 4 | 71 | M | Ae | Adeno | No | 93 | 138 | 264 | Olympus | Yes | Yes | 25 (0.34) | No | Branching |
| 5 | 76 | M | Lt | SCC | DCF | 17 | 57 | 344 | Stryker | Yes | Yes | 25 (0.37) | No | Duplication |
| 6 | 67 | M | Ce | SCC | DCF | 15 | ‐ | 506 | Olympus | No | Yes | 25 (0.34) | No | Typical |
| 7 | 59 | M | Ut | SCC | FP | 37 | 97 | 385 | Stryker | Yes | Yes | 20 (0.40) | No | Duplication |
| 8 | 22 | F | Mt | SCC | DCF | 70 | 112 | 393 | Stryker | Yes | Yes | 20 (0.40) | No | Typical |
| 9 | 68 | M | Mt | SCC | DCF | 35 | 128 | 421 | Stryker | Yes | Yes | 25 (0.39) | No | Typical |
| 10 | 71 | M | Mt | other | DCF | 60 | 119 | 359 | Stryker | Yes | Yes | 25 (0.44) | No | Plexiform |
| 11 | 57 | M | Lt | SCC | DCF | 60 | 126 | 345 | Stryker | Yes | Yes | 25 (0.38) | No | Typical |
| 12 | 57 | M | Lt | Adeno | DCF | 58 | 125 | 461 | Stryker | Yes | Yes | 21 (0.40) | No | Typical |
| 13 | 42 | M | Lt | Adeno | DCF | 66 | 199 | 471 | Stryker | Yes | Yes | 25 (0.27) | No | Typical |
| 14 | 63 | M | Mt | SCC | FP | 41 | ‐ | 424 | Stryker | No | No | 24 (0.41) | No | Could not identify |
| 15 | 67 | M | Ae | Adeno | FP | 42 | 93 | 382 | Stryker | Yes | Yes | 25 (0.31) | No | Typical |
| 16 | 50 | M | Ut | SCC | DCF | 34 | 172 | 400 | Stryker | Yes | Yes | 25 (0.30) | No | Plexiform |
Abbreviations: Adeno, adenocarcinoma; DCF, docetaxel+cisplatin+5‐FU; NAC, neoadjuvant chemotherapy; SCC, squamous cell carcinoma; SII‐CG, inguinal injection of indocyanine green; TD, thoracic duct.
a
Time from subcutaneous injection of ICG to the start or finish of the thoracic operation in min.
b
Time from subcutaneous injection of ICG to the observation of ICG‐induced fluorescence of the thoracic duct.
TD fluorecence and TD recognition fields are bolded for positive results. TD patterns field is bolded where non‐typical anatomy was identified.